NRD
PDSB icon

Nebula Research & Development’s PDS Biotechnology PDSB Stock Holding History

Nebula Research & Development’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,708
Closed -$130K – 829
2023
Q3 		$130K Sell
25,708
-8,898
-26% -$48.7K 0.07% 437
2023
Q2 		$174K Buy
+34,606
New +$227K 0.13% 281

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nebula Research & Development's PDSB Position: Q4 2023 in Review

Nebula Research & Development sold out of PDS Biotechnology (PDSB) in Q4 2023, closing a stake of 25,708 shares — an estimated $130K sold.

Nebula Research & Development first reported a position in PDSB in Q2 2023 and held it in 2 quarters. The position peaked at $174K in Q2 2023. 77 funds tracked by Wall St. Rank hold PDSB as of Q4 2023.

  • Nebula Research & Development reported no remaining PDS Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Nebula Research & Development sold 25,708 PDS Biotechnology shares in Q4 2023, an estimated $130K.
  • Nebula Research & Development first reported a position in PDS Biotechnology in Q2 2023 and held it in 2 quarters.
  • Nebula Research & Development's PDS Biotechnology position peaked at $174K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2023.

Based on Nebula Research & Development's 13F filing for Q4 2023, filed 14 Feb 2024.